Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2026)

Amneal Pharmaceuticals has reported Tax Provisions for 10 years, with the latest figure at $1.4 million in Q2 2026.

• On a quarterly basis, Tax Provisions fell 91.45% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 137.16% decrease from a year earlier, with the FY2025 full-year figure at $11.3 million, down 40.22% from the prior year.
• Tax Provisions was $1.4 million for Q2 2026 at Amneal Pharmaceuticals, down from $2.2 million in the prior quarter.
• The five-year high for Tax Provisions was $16.1 million in Q2 2025, with the low at -$23.4 million in Q3 2025.
• Average Tax Provisions over 5 years is $2.7 million, with a median of $3.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Tax Provisions tumbled 975.0% in 2022, then soared 15830.43% in 2024.
• Over 5 years, Tax Provisions stood at -$1.8 million in 2022, then jumped by 649.06% to $9.9 million in 2023, then sank by 45.13% to $5.4 million in 2024, then rose by 4.41% to $5.7 million in 2025, then tumbled by 75.7% to $1.4 million in 2026.
• The last three Tax Provisions figures came in at $1.4 million (Q2 2026), $2.2 million (Q1 2026), and $5.7 million (Q4 2025), per Business Quant data.